Summit Therapeutics Inc. (SMMT) Institutional Ownership

Ownership Summary

Summit Therapeutics Inc. (NASDAQ:SMMT) has 202 institutional investors that have filed 13F reports for the period ending December 2025.

• Collectively, these holders controlled 14.6% of Summit Therapeutics's outstanding shares in December 2025, up from 14.0% in September 2025.
• Their total shares held in SMMT increased 13.38% from the prior quarter, while the number of investors in Summit Therapeutics stayed flat year over year.
• During the quarter, 107 of these 202 funds increased positions in SMMT, 65 reduced exposure, and 30 held steady.
• In total, institutional investors held 108.46Mn shares in Summit Therapeutics as of December 2025, up by 12.8Mn shares quarter on quarter, and up 15.02Mn shares year over year.
• BAKER BROS. ADVISORS LP holds the largest position in SMMT at 36.39Mn shares as of December 31, 2025, or 4.9% of shares outstanding.
• The biggest buyers of Summit Therapeutics for the quarter ending December 2025 included PRICE T ROWE ASSOCIATES INC /MD/ (8.28Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.71Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (5.23Mn), UBS Group AG (2.81Mn), D. E. Shaw & Co., Inc. (1.83Mn).
• The largest sales of SMMT for the quarter ending December 2025 came from FMR LLC (2.51Mn), CITADEL ADVISORS LLC (2.03Mn), Polymer Capital Management (HK) LTD (1.29Mn), Goldman Sachs Group Inc (660.4K), MILLENNIUM MANAGEMENT LLC (342.74K).
• According to Business Quant data, leading holders of SMMT for December 2025 are BAKER BROS. ADVISORS LP (36.39Mn), FMR LLC (10.85Mn), BlackRock, Inc. (9.65Mn), PRICE T ROWE ASSOCIATES INC /MD/ (8.28Mn), State Street Corp (7.03Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.71Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (5.23Mn), UBS Group AG (3.68Mn), GEODE CAPITAL MANAGEMENT, LLC (3.32Mn), D. E. Shaw & Co., Inc. (2.24Mn).